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KIRThe development of next-generation sequencing (NGS) technologies for HLA and KIR genotyping is
rapidly advancing knowledge of genetic variation of these highly polymorphic loci. NGS genotyping is
poised to replace older methods for clinical use, but standard methods for reporting and exchanging
these new, high quality genotype data are needed. The Immunogenomic NGS Consortium, a broad
collaboration of histocompatibility and immunogenetics clinicians, researchers, instrument manufactur-
ers and software developers, has developed the Minimum Information for Reporting Immunogenomic
NGS Genotyping (MIRING) reporting guidelines. MIRING is a checklist that specifies the content of NGS
genotyping results as well as a set of messaging guidelines for reporting the results. A MIRING message
includes five categories of structured information – message annotation, reference context, full genotype,oratory;
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Data standardsconsensus sequence and novel polymorphism – and references to three categories of accessory informa-
tion – NGS platform documentation, read processing documentation and primary data. These eight cat-
egories of information ensure the long-term portability and broad application of this NGS data for all
current histocompatibility and immunogenetics use cases. In addition, MIRING can be extended to allow
the reporting of genotype data generated using pre-NGS technologies. Because genotyping results
reported using MIRING are easily updated in accordance with reference and nomenclature databases,
MIRING represents a bold departure from previous methods of reporting HLA and KIR genotyping results,
which have provided static and less-portable data. More information about MIRING can be found online
at miring.immunogenomics.org.
 2015 The Authors. Published by Elsevier Inc. on behalf of American Society for Histocompatibility and
Immunogenetics. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Next-generation sequencing (NGS) offers high-throughput gen-
eration of phased sequences for the highly polymorphic human
leucocyte antigen (HLA) and killer-cell immunoglobulin-like recep-
tor (KIR) genes, allowing their rapid, high-resolution genotyping.
NGS methods may be more generally described as single-
molecule sequencing methods [1]. In some cases, these methods
offer full-gene sequence results [1–4]. In general, all NGS methods
offer higher resolution and lower ambiguity genotypes than stan-
dard methods such as ‘‘Sanger” sequencing based typing (SBT),
and sequence-specific oligonucleotide probe (SSOP) or primer
(SSP) methods [3–6], and do not require the use of secondary geno-
typing methods to resolve ambiguities.
Any method for genotyping HLA and KIR using genomic DNA
requires at least three components: the genotyping instrument,
reference sequences, and analysis software. The genotyping
instrument generates primary sequence data, which is interpreted
by the analysis software, using the reference sequences to identify
the subject’s genotype. A wide variety of instruments, reference
sequence resources, and data analysis programs are available for
both NGS and pre-NGS genotyping approaches, and are used in dif-
ferent combinations.
In some cases, the different methods may not generate the same
results for a given subject. Such discrepancies may derive from the
instrumentation, reference sequences, software, or a combination
of these components. However, as Hollenbach et al. [7] have
described, there is no standard format for reporting a genotyping
result or for documenting the components that were applied to
generate that result. In the absence of such documentation, the
source of discrepancies in genotyping results is rarely identifiable.
In addition, it becomes impossible to directly relate the HLA and
KIR genotypes of subjects genotyped using different methods, as
genetic differences between individuals may not be distinguish-
able from methodological differences between genotyping
approaches. This lack of clarity has important implications for
meta-analytical approaches to population or disease association
studies that seek to combine and compare data across different
studies. In general, ambiguity regarding the source of genotyping
discrepancies impedes technical advances and optimization, and
frustrates reproducible research.
Guidelines for reporting and documenting genotyping results
are essential for evaluating HLA and KIR genotypes generated using
different instruments, reference sequences or data-analysis pro-
grams. The active and ongoing development of NGS methods
requires the adoption of a single extensible and adaptable standard
for reporting and documenting NGS genotyping results.
Here we describe the Minimum Information for Reporting NGS
Genotyping (MIRING) checklist, a set of Minimum Information for
Biological and Biomedical Investigations (MIBBI) [8,9] reporting
guidelines developed by a consortium of immunogenomicresearchers and clinicians, NGS instrumentmanufacturers and soft-
ware developers, HLA and KIR sequence database developers and
administrators, bone marrow donor registries and donor centers.2. Description of MIRING
2.1. MIRING development
The standard reporting of HLA and KIR genotypes is a long
unmet need of the histocompatibility and immunogenetics com-
munity [7,10–14]. The specific need for NGS genotype reporting
guidelines emerged from a survey of immunogenomic data man-
agement and analysis practices [15], carried out by the Immunoge-
nomic Data Analysis Working Group (IDAWG) as part of the 16th
International HLA and Immunogenetics Workshop (IHIW) [16].
The survey uncovered a lack of consistency between laboratories
and the resulting impact on downstream analytical results. The
development of MIRING began with the formation of the
Immunogenomic Next Generation Sequencing Data Consortium
(INGSDC) (ngs.immunogenomics.org) by the IDAWG and the HLA
Information Exchange Data Format Standards (HIEDFS) group.
The INGSDC met several times between 2012 and 2014, and iden-
tified the minimum information needed to accurately report NGS
genotyping results for the HLA and KIR genes for clinical and
research applications. Further MIRING development took place as
part of the BeTheMatch Foundation’s Data Standards ‘Hackathons’
for NGS-based typing held in September of 2014 and February of
2015 (dash.immunogenomics.org). Implementations of MIRING
are being evaluated as part of a 17th IHIW Informatics Component
(ihiws.org/informatics-of-genomic-data/) project; bioinformatic
tools for generating, exchanging and consuming MIRING messages
are being developed as part of this project as well. The participa-
tion of interested investigators in this IHIWS project is welcome.
2.2. MIRING goals
To meet the current needs of the histocompatibility and
immunogenetics community for reporting and exchanging NGS
genotype data, the elements of a MIRING message were designed
with the following goals:
1. To facilitate downstream analyses and data management for
current research and clinical use cases for molecular genotyping
data in the histocompatibility and immunogenetics field.
2. To permit the re-analysis of NGS HLA or KIR genotyping results
in the context of past, present and (foreseeable) future molecu-
lar nomenclatures and methods of describing HLA and KIR allele
diversity.
3. To permit the comparison and evaluation of genotyping perfor-
mance between different NGS platforms and analysis methods.
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SSOP and SSP genotyping technologies to be incorporated if
required.
5. That the MIRING elements be sufficient to permit the accurate
reporting of NGS data generated for other highly-polymorphic
regions of the human genome.
2.3. MIRING elements
MIRING is both a checklist of elements that constitute a NGS
HLA or KIR genotyping result, and a set of messaging guidelines
for transmitting that NGS HLA or KIR genotyping result. Genotyping
reports can be generated from a MIRING message. The MIRING
guidelines include semantic definitions for a MIRING message,
but are not intended to impose syntactic constraints on the mes-
sage; they are principles that must be met, regardless of the struc-
ture of the message.
MIRING comprises eight primary elements, and their con-
stituents (Table 1). Elements 1–5 constitute the MIRING message,
suitable for reporting a genotyping result. Elements 6–8 constitute
the contextual resource for MIRING messages, but are not included
in MIRING messages; instead, these elements are referenced in
MIRING messages. Where possible, MIRING elements are consis-
tent with established formats for describing genetic and genomic
data (e.g., FASTA [17–19], FASTQ [20], variant call format (VCF)
[21] and Genotype List (GL) String formats [22]), and leverage
existing genetic and genomic data-resources (e.g., the IMGT/HLA
and IPD-KIR Databases [23], the NCBI Genetic Testing Registry
(GTR) [24] and International Nucleotide Sequence Database
Collaboration (INSDC) [25]).
2.3.1. MIRING element 1: message annotation
Each MIRING message must include a unique identifier that
links the message contents to external information excluded from
the MIRING message. For example, individual subject identifiers
protected by the U.S. Health Insurance Portability and
Accountability Act of 1996 (HIPAA) [26], the Canadian Personal
Information Protection and Electronic Documents Act (PIPEDA)
[27], and EU Directive 95/46/EC [28] are excluded from MIRING
messages, and should be reported and transmitted outside the
scope of the message. MIRING message annotation must allow
unambiguous identification of the organization that generated
the message, as well as the unambiguous identification of any
MIRING message generated by that organization. For example,
organizations can be identified unambiguously using an
International Organization for Standardization (ISO)/International
Electrotechnical Commission (IEC) standard 6523 organization
identifier (OID) [29,30]. MIRING message annotation must also
include contact information for the organization that generated
the message, along with references to the location and availability
of platform (MIRING element 6) and read processing (MIRING ele-
ment 7) documentation, and the primary data (MIRING element 8)
from which the MIRING message was generated.
2.3.2. MIRING element 2: reference context
Comparison to specific well-characterized and annotated refer-
ence sequences is crucial for NGS genotyping of HLA and KIR genes.
Reference sequences may be used for the mapping and processing
of reads, as well as for the determination of a genotype based on a
consensus sequence. These sequences are stored in a variety of
databases, including the Genome Reference Consortium (GRC)
[31] and IMGT/HLA and IPD-KIR Databases [23]. Clear identifica-
tion both of the database versions and of the individual sequences
applied in an NGS genotyping must be included in each MIRING
message. For example, GRCh38.p4 or IMGT/HLA Database release
3.21.1 describe the current versions of the GRC human genomeand IMGT/HLA Databases, respectively; GL000251.2. and
HLA00001 are the accession numbers for the GRCh38.p4 alternate
reference locus number 2, (derived from the COX cell line) and
IMGT/HLA Database HLA-A⁄01:01:01:01 allele, respectively.
Any reference database or individual reference sequence used
to generate a NGS genotype should be documented as part of
MIRING element 2. To allow the assessment of the confidence in
the genotyping, this documentation should indicate whether or
not the database is public, and if a public database is curated. If
no reference database is used, this should also be indicated. For
instances when either previously unexplored gene features (e.g.,
HLA-DRB5 introns) or a genomic region that is unrepresented in
any genomic alignment (e.g., DR1 or DR8 haplotypes of the
HLA-DRB region [32]) is being sequenced, the absence of available
reference sequence at the time of the genotyping should be noted.
2.3.3. MIRING element 3: full genotype
Some NGS methods provide phased, full-gene resolution data.
However, many NGS genotyping approaches do not return such
results, and genotyping ambiguity [7] is not resolved. In order to
evaluate genotyping results across specimens, NGS instruments,
genotyping and analysis methods, the complete set of alleles and
genotype combinations that are possible for a given set of
sequence data using a given reference sequence database must
be provided.
GL String [22] format can be used to describe the genotype at
each locus, including genotyping ambiguity and known allelic
phase between loci. A ‘‘best guess,” estimate or imputation of an
unambiguous genotype should not be included in a MIRING mes-
sage. When available, a reference to an external uniform resource
identifier (URI) for the GL String should be included as well.
In addition, genes that were specifically targeted, but yielded no
sequence data should be explicitly identified. Due to structural
variation among the HLA [32] and KIR loci [33–35], genes that
are present in some individuals may be completely absent in
others. For example, individuals homozygous for HLA-DRB1⁄01
alleles have no HLA-DRB3, HLA-DRB4 or HLA-DRB5 genes [32], and
individuals homozygous for the KIR A haplotype have no KIR2DS1,
KIR2DS3/5 or KIR2DL5A genes [33]. When a gene could have been
detected by a given NGS instrument, but no sequence for that gene
is generated for a subject, the locus in question should be identified
in the MIRINGmessage, with the genotype reported as ‘‘Absent” for
that locus.
2.3.4. MIRING element 4: consensus sequence
Depending on the NGS approach applied, consensus sequence
for an individual reported allele may be generated as a single,
gene-length consensus sequence block (CSB) (e.g., resulting from
de novo assembly), or as shorter phased or unphased CSBs (e.g.,
corresponding to individual exons). These sequences should be
written using the single-letter symbols for nucleotide bases and
incompletely specified bases defined by the International Union
of Pure and Applied Chemistry (IUPAC) and International Union
of Biochemistry and Molecular Biology (IUBMB) [36]. Two CSBs
would be reported for heterozygous individuals where complete
phase was known for a given gene.
Each CSB should be accompanied by MIRING elements 4.2.1–
4.2.7, which identify the CSB, the reference sequence (as defined
in MIRING element 2) to which it has been aligned along with its
position and identity to that reference sequence, or the absence
of a reference sequence, any phase and continuity between CSBs,
and the inferred copy number for each CSB. For diploid loci, the
copy number values for homologous CSBs should sum to 2; how-
ever, due to copy number variation of some HLA and KIR genes
[32,33], some individuals are truly haploid for a given gene (copy
number of 1), while others may have more than two copies of a
Table 1
Definition of MIRING elements and formats.
Number Element Components Messaging instructions and notes
1 Message
annotation
1.1 Unique MIRING message identifier Identifies the MIRING message generator (e.g., an International Organization for Standardization
(ISO)/International Electrotechnical Commission (IEC) standard 6523 organization identifier
(OID) [28,29]) and the specific MIRING message
1.2 Message generator contact
information
Email, mailing address, website, phone number, etc.
1.3 Platform documentation (MIRING
element 6) Reference
e.g., citation of a peer-reviewed publication or an entry in the National Center for Biotechnology
Information (NCBI) Genetic Testing Registry (GTR) (ncbi.nlm.nih.gov/gtr/)
1.4 Read processing documentation
(MIRING element 7) reference
A reference to the location of a structured report documenting the use of programs/scripts
(including parameters and order of use) to process the primary read data in order to make allele
calls
1.5 Primary data availability A: Public, and available as defined in MIRING element 1.6
B: Private, and potentially available by contacting the message generator as defined in MIRING
element 1.2
1.6 Primary data (MIRING element 8)
reference
Provided when permitted
e.g., referenced to data in the NCBI Sequence Read Archive (SRA) (ncbi.nlm.nih.gov/sra/)
2 Reference context
2.1 Reference sequence database
version for allele calling
Identify for each locus included in the message
2.2 Individual reference sequences
applied
Identify the source database and accession number of each individual sequence applied in the
message
2.2.1 Reference Sequence Identifier A unique identifier ranging from 0 to n – 1, where n is the number of reference sequences in
MIRING element 2.2
2.3 Reference Sequence Source Type Specified for MIRING elements 2.1 and 2.2
A: Public and curated
B: Public and uncurated
C: Not public
D: No reference
3 Full genotype Defined in MIRING elements 3.1 and 3.2
3.1 Pertinent locus/loci Genetic loci as defined in an International Nucleotide Sequence Database Collaboration (INSDC)
resource [24]. All of the loci tested as part of the work reported in the MIRING message should be
included
3.2 Formatted genotype If a genotype is detected for a given locus, report that genotype in Genotype List (GL) String
format [21], or an equivalent format. If a locus is identified in MIRING element 3.1, but no
sequence data are generated for that locus, report that genotype as ‘Absent’ in the GL String
3.3 Genotype uniform resource
identifier (URI)
e.g., derived from the GL Service (gl.nmdp.org)
4 Consensus
sequence
The use of MIRING elements 4.1 and 4.2 to describe the consensus sequence allows the
sequences to be reported in FASTA format [16–18]. FASTA format is not a required component of
a MIRING message, but a FASTA formatted component of a MIRING-derived genotype report
should use the pipe-delimited header format described in 4.2
4.1 Consensus sequence block (CSB) A contiguous nucleotide sequence organized in the 50–30 direction and written using IUPAC and
IUBMB nucleotide base symbols [35]. Multiple sequence blocks may be included in a MIRING
message
4.2 Consensus Sequence Descriptor For FASTA representations of consensus sequence, assign each CSB a pipe-delimited descriptor
comprised by MIRING elements 4.2.1–4.2.7
4.2.1 Consensus sequence block
identifier
Ranges from 0 to n-1, where n is the number of CSBs included in the message. CSB identifier
numbers must increase in the 5’ to 3’ order of CSBs
4.2.2 Reference Sequence Identifier MIRING Element 2.2.1 pertinent to each CSB. If the reference sequence is identified as being of
type D (no Reference; MIRING element 2.3) the entire CSB is considered to be a novel
polymorphism, but does not need to be independently documented as part of MIRING element 5.
4.2.3 Reference Sequence Coordinate The position in the reference sequence (MIRING element 2.2.1) (indexed from 0) corresponding
to the 1st position of the CSB
4.2.4 Phase set When phase information is available, identify the lowest numbered CSB (using MIRING element
4.2.1) sharing phase with a given CSB; assign the lowest numbered CSB in a phase set its own CSB
identifier
If no phase information is available for a given CSB, assign that CSB its own CSB identifier
4.2.5 Copy number 1 to n, where n is the number of distinct sequences represented by the CSB (e.g., haploid = 1,
diploid = 2, etc.)
4.2.6 Reference sequence match 1: CSB exactly matches the sequence range (MIRING element 4.2.3) of the reference sequence
(MIRING Element 2.2.1)
0: CSB does not exactly match the sequence range of the reference sequence
When reference sequence match = 0, a description of novel polymorphisms (MIRING element 5)
is expected unless value for MIRING element 2.3 = D
4.2.7 Sequence continuity 1: no sequence gaps occur between a given CSB and the preceding CSB in the same phase set
0: there is no phase information for this consensus sequence block, or there is a sequence gap
between this CSB and the preceding CSB
5 Novel
polymorphisms
Define novel polymorphisms (identified in MIRING element 4.2.6) using MIRING elements 5.1–
5.8. These elements allow novel polymorphisms to be reported using variant call format (VCF)
[20] or an equivalent. VCF is not a required component of a MIRING message, but a VCF
component of a MIRING-derived genotype report should use the format described in elements
5.1–5.8
(continued on next page)
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Table 1 (continued)
Number Element Components Messaging instructions and notes
5.1 Reference MIRING element 2.2.1
5.2 Position The position in the reference sequence (MIRING element 2.2.1) (indexed from 1) corresponding
to the position of the reported variant sequence
5.3 Variant identifier A composite value comprised by the CSB identifier including the variant, and a number ranging
from 0 to n-1, where n is the number of sequence variants reported, separated by a pipe (e.g. 0|
12)
5.4 Reference sequence The sequence in the reference (MIRING element 2.2.1) at the position (MIRING element 5.2)
5.5 Variant sequence The variant sequence identified at the position (MIRING element 5.2). This is the equivalent of
the VCF ALT column [20]
5.6 Quality score Quality score for the sequence variant reported in MIRING element 5.5. This is the equivalent of
the VCF QUAL column [20]
5.7 Quality filter status PASS or FAIL value for MIRING element 5.6
5.8 INSDC Accession Number When possible, provide a GenBank or EMBL-ENA accession number for the novel sequence
6 Platform
documentation
A peer-reviewed publication, or the identifier of a record deposited in the NCBI GTR or an
equivalent resource, documenting the specific details of the methodology and pertinent versions
of the platform and instrument-dependent analysis software applied to obtain the unmapped
reads and quality scores (MIRING element 8)
Relevant platform-dependent information must include: instrument version, instrument-
dependent software version identifier(s), reagent versions and lot number, sequence read
lengths, expected amplicon/insert length, reference sequences applied, and sequence feature/
region targeted
Inclusion of primer target locations is optional
7 Read processing
documentation
The specific details of the instrument-independent processing of the primary data (MIRING
element 8), documented using the SRA Analysis XSD XML Schema [37] or an equivalent; e.g.,
instrument-independent analysis software version identifier(s), analysis software parameters
used, details of the cutoff values and reference sequences (defined in MIRING element 2) used to
filter the data for read quality and/or mapping quality, along with the final read depth obtained
and a confidence score of the zygosity for the SNPs used to infer the final genotype
This information is not included in the MIRING message, but must be associated with the
primary data (MIRING element 8) by the message generator, and can be accessed using MIRING
element 1
8 Primary data When permitted, unmapped reads with quality scores (e.g., Sanger FASTQ [19] or standard
flowgram format (SFF) [39] formatted files), as generated by the instrument (defined in MIRING
element 6), must be retained and should be made available as the primary NGS data. Adapter
sequences may be excluded from the primary data. These primary data are not included in the
MIRING message, but are accessed using MIRING element 1
958 S.J. Mack et al. / Human Immunology 76 (2015) 954–962given gene (e.g., copy number of 3 or 4). For example, some indi-
viduals have four copies of the KIR2DS3 and KIR2DL5 genes [33].
A CSB can be described in FASTA format by including a header
line that comprises MIRING elements 4.2.1–4.2.7, formatted as
defined in Table 1 and illustrated in Fig. 1. Although this header
format should be used for FASTA presentation of CSBs in a
genotyping report, MIRING elements 4.2.1–4.2.7 can be recorded
separately and differently within a MIRING message.2.3.5. MIRING element 5: novel sequence polymorphisms
The HLA and KIR genes are highly polymorphic, and the number
of alleles reported to public databases is expected to increase dra-
matically with the use of NGS genotyping [37]. In the context of a
MIRING message, novel polymorphism includes nucleotide
sequence variants not yet present in a curated, public reference
sequence database (e.g., the IMGT/HLA Database). The explicit
identification of novel polymorphisms is an important element of
both clinical and research genotyping, and must be documented
in a MIRING message. Depending on how a MIRING message is
generated, a CSB (as defined in MIRING element 4) representing
novel sequence variants may have been submitted to a non-
curated public reference sequence database [e.g., GenBank or the
European Molecular Biology Laboratory (EMBL) European
Nucleotide Archive (ENA)] as a novel sequence.
Novel sequence variants can be described through the use of
MIRING elements 5.1–5.8, which define the reference sequence,
variant position, variant sequence, quality score and quality filter
status, and (if available) a GenBank or EMBL-ENA accession num-
ber for the novel sequence (e.g. L28096). This accession numbercan be included in the GL String (MIRING element 4.2.2, e.g.
HLA-DRB1⁄L28096).
Use of MIRING elements 5.1–5.8 is sufficient to describe novel
sequence variants in VCF as part of a genotyping report. A GenBank
or EMBL-ENA accession number can be linked to the variant iden-
tifier (MIRING element 5.3) in the VCF meta-data. However, actual
VCF is not a required component of a MIRING message, and
MIRING elements 5.1–5.8 can be recorded separately and differ-
ently within a MIRING message.
2.3.6. MIRING element 6: platform documentation
The specifics of each instrument, methodological approach (e.g.,
whole-genome sequencing, target enrichment, targeted amplicon
sequencing) and reagent set applied to generate the primary read
data (MIRING element 8) upon which the genotyping result is
based should be documented. This documentation can take the
form of a citation to a peer-reviewed publication or a reference
to a structured documentation of the instrument and methodology
in a publically accessible resource (e.g., the NCBI’s Genetic Testing
Registry (GTR)). This documentation is not included in the MIRING
message, but the reference to the resource must be included in
MIRING element 1.
2.3.7. MIRING element 7: read processing documentation
After the primary read data (MIRING element 8) have been gen-
erated by the NGS instrument, they may be scrutinized for quality
and length, modified or subjected to various bioinformatics filters
before allele calls are made and a genotype result is generated.
To enable the replication of the genotyping result and the
(B)
(A)
(C)
Fig. 1. FASTA consensus sequence blocks with MIRING headers. Consensus sequences in MIRING messages are arranged in consensus sequence blocks (CSBs). CSBs are
equivalent to FASTA formatted sequences that use a MIRING-specific descriptor as the header line. CSBs representing phased exon 2 and exon 3 sequences for an HLA-A allele
are shown in (A) and (B). A MIRING CSB descriptor consists of seven fields of information, delimited by pipes (|) as shown in (C). Each CSB is identified with a unique index,
beginning from 0, in the consensus sequence block identifier field. CSB identifiers must increase in the 50–30 direction of CSBs. Each reference sequence is identified with a
unique index, beginning from 0, in the Reference Sequence Identifier field. Each index is defined in MIRING element 2. The Reference Sequence Coordinate field identifies the
first position of the pertinent CSB in the pertinent reference sequence. The Phasing Group field identifies CSBs between which phase is known. Each set of phased CSBs will be
identified with the same index, beginning from 0. The Copy Number field identifies the number of distinct sequences represented by each CSB (e.g., 1 = haploid, 2 = diploid,
etc.). The Reference Sequence Match field identifies CSBs that exactly match the sequence range of the pertinent reference sequence (value = 1) or that do not match the
sequence range of the reference sequence (value = 0). When phase is indicated for CSBs, the Sequence Continuity field indicates if there are gaps (of any size) between those
phased CSBs. A value of 1 in this field indicates that there are no gaps between the pertinent CSB and the most immediately 50 CSB in phase with that CSB. A value of 0 in this
field indicates a sequence gap between the pertinent CSB and the most immediately 50 CSB in phase, or that no phase information is available for the pertinent CSB. (A) CSB 0
and header, (B) CSB 1 and header, (C) Guide to interpreting the MIRING headers. 1: Reference sequence for CSB 0 is IMGT/HLA Database release version 3.21.1 A_nuc.fasta
HLA00005 HLA-A⁄02:01:01:01. Reference sequence for CSB 1 is IMGT/HLA Database release version 3.21.1 A_nuc.fasta HLA10254 HLA-A⁄66:01:02.
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version used for both the genotyping and the processing steps
applied must be documented. While these read processing steps
are idiosyncratic to the combination of NGS components that have
been applied in the genotyping effort, they can be accommodated
in the NCBI’s Sequence Read Archive (SRA) Analysis XSD XML
Schema [38,39]. Each MIRING message should reference a report,
based on the Analysis XSD or an equivalent, describing each pro-
gram or script applied in the processing of reads, the order in
which they were applied, the software versions and the pertinent
parameters used. Where possible, this report should be associated
with the primary read data (MIRING element 8), or made available
by the MIRING message generator. This report should not be
included in the MIRING message, but a reference to the location
of the read processing documentation, or instructions for obtaining
access to that documentation, should be included in MIRING ele-
ment 1.2.3.8. MIRING element 8: primary data
The reads generated by the NGS instrument applied for the typ-
ing should be made available for re-analysis, either via deposition
in a public database [e.g., the SRA, NCBI’s Genotype and Phenotype
database (dbGAP) or an equivalent] or directly from the data gen-
erators. Primary data should take the form of unmapped reads with
quality scores (e.g. Sanger FASTQ, SFF [40], or unmapped BAM
including quality scores). The primary data are not included in
the MIRING message, but a reference to the location of the primary
data, or instructions for obtaining access to those data, should be
included in MIRING element 1.
Because each MIRING message is assigned a unique identifier
(MIRING element 1), it is possible for a MIRING message generator
to produce multiple distinct messages for a single specimen from
one set of primary data. Depending on read processing parameters
applied and references used, each message may use a different
subset of reads. Therefore, the MIRING message generator must
maintain an archive for a given set of primary data, which identi-
fies the reads pertinent to each MIRING message. When the pri-
mary data are publically available (as defined as part of MIRING
element 1), the MIRING message generator must make this infor-
mation available as well.3. Strengths and limitations of MIRING
MIRING represents a bold departure from previous methods of
reporting HLA and KIR genotyping results. Previously, genotyping
results have been maintained as static entities constrained by the
existing references and nomenclature, with insufficient reference
context and sequence information provided to foster genotype
reassessment. By contrast, MIRING elements 3–5 are dynamic in
that they can change with the reference context (MIRING element
2) – for instance when the database is updated. By providing access
to the primary read data, and by including the consensus sequence
in the MIRING message, the genotype and novel polymorphism
information in a MIRING message can be updated with each refer-
ence allele sequence database revision.
The MIRING checklist identifies the minimum information
needed to provide adequate documentation of an NGS HLA and
KIR genotype. This documentation should be sufficient to repro-
duce or permit the reinterpretation of the reported genotype from
the primary read data, and to allow informed comparisons of geno-
typing results for the same subject generated using different NGS
genotyping instruments, reference sequences and analytical soft-
ware. In cases when such genotyping results differ, use of MIRING
messages to report those genotypes should facilitate the rapid
identification of the sources of such discrepancies.Many pieces of information pertinent to a genotyping experi-
ment are not included in MIRING messages. Protected subject
identifiers, phenotypic and demographic subject details, specimen
details (e.g., preparation, quantification), specifics of the activity
for which the genotyping effort was undertaken, descriptions and
selection criteria for the loci genotyped, interpretations of the
genotyping result (e.g., a ‘best call’ for ambiguous genotypes, or
identifying a donor as a match to a patient), and funding sources
for the genotyping are excluded from MIRING messages. Although
this information can be associated with MIRING messages as part
of a larger message if required, MIRING’s main purpose is to docu-
ment those elements of a genotyping experiment that foster the
archival utility of the genotyping result.
The MIRING checklist has been developed via community con-
sensus, in order to meet the data management and exchange needs
of the histocompatibility and immunogenetics community. Much
of the information included in a MIRING message will not be per-
tinent to all current HLA and KIR genotyping use cases (e.g., clinical
care, basic research, instrument validation, software development),
but all such use cases can be met using the same MIRING message.
Applications that parse MIRING messages and provide information
tailored to each use case will make use of the same message. Given
the rapid exploration of NGS technologies and methodologies, use
of MIRING messages will allow the transparent evaluation of dif-
ferent instruments and genotyping approaches, encouraging
improvement and standardization of all NGS methods.
The elements of the MIRING checklist allow MIRING messages
to pertain to a single locus or multiple loci, but not to multiple sub-
jects. Data for discrete subjects are reported in distinct MIRING
messages, and multiple messages can be generated for each
subject. Proper management of MIRING message identifiers then
becomes an essential part of the MIRING messaging system. A
central repository for MIRING messages will greatly facilitate and
simplify the exchange of genotyping results among centers and
researchers.
As illustrated in Fig. 2, the elements of a MIRINGmessage can be
divided into distinct categories. MIRING elements 6–8 are specific
to NGS methodologies, but are not included in the MIRING mes-
sage. Therefore, MIRING messaging could be extended to include
other genotyping methodologies (e.g., SBT, SSOP or SSP) by
broadening the scope of information reported in elements 6–8 to
document the methodologies, software, and raw data pertinent
to these other methodologies. However, the structure or content
of MIRING elements 1–5 would not change. Only the details of
the MIRING message would change; for example, CSBs would
decrease in length for SSOP- and SSP-based MIRING messages, to
accommodate the shorter length of the hybridized sequences
[41], and ambiguity in the full genotypes reported would increase.
CSB copy number values would change from 1 (haploid) to 2
(diploid) for most Sanger sequencing-based MIRING messages
(unless sequencing was applied to isolated chromosomes, or on
the basis of group-specific amplification [42]).
Although, the MIRING checklist was developed with HLA and
KIR genotypes in mind, it can be applied to report genotype data
for any highly-polymorphic genetic system. In addition, MIRING
is sufficiently flexible that it can accommodate future develop-
ments in sequencing technology. As the cost of generating high-
quality genomic information decreases, the need to report and
exchange these data in a straightforward and reproducible manner
will increase. As genomic data accumulate, specific genes,
haplotype-blocks and chromosomal regions will be revealed as
medically relevant, and their polymorphism can be documented
and reported via a MIRING message.
Examples of Histoimmunogenetics Markup Language version
1.0 messages that comply with MIRING standards and principles
are included in the paper by Milius et al. [43] included in this issue.
Fig. 2. MIRING Checklist Categories. The eight elements of the MIRING checklist are either included in a MIRING message or exist as accessory data that are referenced in the
MIRING message. MIRING message elements 1 and 2 and 6–8 are static in that they pertain to events that occurred when the genotyping instrument was applied to generate
the primary read data. MIRING elements 3–5 are dynamic in that they can change if MIRING element 2, changes (e.g., a future release of the IPD-KIR database may result in a
change to the ambiguity level of a genotype). MIRING elements 6–8 are also specific to NGS platforms. Valid MIRING messages could be generated on the basis of Sanger
sequence-based typing (SBT), sequence-specific oligonucleotide probe (SSOP) and priming (SSP) methods, requiring changes to the content of MIRING elements 6–8 alone.
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MIRINGmessages foster the portability of HLA and KIR genotype
data in a standard format, allowing the dynamic re-analysis of
these medically important results in the context of continual geno-
mic discovery. The data recorded in a MIRING message are essen-
tial for the systematic traceability of a NGS genotyping result; this
traceability is critical for reproducible research and the meaningful
archiving of modern genotyping results. The MIRING checklist is
sufficiently broad in scope that genotyping results generated using
NGS technologies, older genotyping technologies and future meth-
ods can be accommodated in a MIRING message. Reporting of NGS
genotype data as MIRING messages promotes transparency across
varying applications of NGS components, facilitating comparison,
and therefore the improvement and ongoing development of NGS
technology. Finally, the widespread application of the MIRING
checklist for exchanging NGS genotyping results will allow the
leveraging of public data resources for meta-analysis, study repli-
cation and new discovery. More information about MIRING can
be found online at miring.immunogenomics.org.
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